January 7, 2012Bristol-Myers Squibb to Acquire InhibitexDecember 22, 2011Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer’s DiseaseNovember 7, 2011FDA Approves ERBITUX® (cetuximab) for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-FluorouracilNovember 3, 2011ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership to License and Develop Investigational Oncology CompoundSeptember 22, 2011Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart FailureSeptember 20, 2011Bristol-Myers Squibb and Ono Enter into Strategic Agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)September 8, 2011Bristol-Myers Squibb Completes Acquisition of Amira PharmaceuticalsJuly 21, 2011Bristol-Myers Squibb to Acquire Amira PharmaceuticalsJuly 6, 2011Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology BiologicJune 2, 2011Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY™ (ipilimumab) and VemurafenibMarch 8, 2011FDA Accepts New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 DiabetesMarch 7, 2011Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing FacilityFebruary 23, 2011ONGLYZA™ (saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use in Renally Impaired Adults with Type 2 DiabetesFebruary 2, 2011Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of NecitumumabJanuary 10, 2011Bristol-Myers Squibb and Pharmasset Enter into a Clinical Collaboration Agreement for Proof of Concept Combination Study in Patients Chronically Infected with Hepatitis CDecember 20, 2010Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement for Investigational HIV CompoundDecember 7, 2010Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma Presented at 52nd American Society of Hematology Annual MeetingDecember 6, 2010Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month DataOctober 28, 2010FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic PhaseOctober 12, 2010Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc.
|
|